ABSTRACT
Background We tested if fatigue in incident Peritoneal Dialysis associated with an increased risk for mortality, independently from main confounders.
Methods We conducted a side-by-side study from two of incident PD patients in Brazil and the United States. We used the same code to independently analyze data in both countries during 2004 to 2011. We included data from adults who completed KDQOL-SF vitality subscale within 90 days after starting PD. Vitality score was categorized in four groups: >50 (high vitality), ≥40 to ≤50 (moderate vitality), >35 to <40 (moderate fatigue), ≤35 (high fatigue; reference group). In each country’s cohort, we built four distinct models to estimate the associations between vitality (exposure) and all-cause mortality (outcome): (i) Cox regression model; (ii) competitive risk model accounting for technique failure events; (iii) multilevel survival model of clinic-level clusters; (iv) multivariate regression model with smoothing splines treating vitality as a continuous measure. Analyses were adjusted for age, comorbidities, PD modality, hemoglobin, and albumin. A mixed-effects meta-analysis was used to pool hazard ratios (HRs) from both cohorts to model mortality risk for each 10-unit increase in vitality.
Results We used data from 4,285 PD patients (Brazil n=1,388 and United States n=2,897). Model estimates showed lower vitality levels within 90 days of starting PD were associated with a higher risk of mortality, which was consistent in Brazil and the United States cohorts. In the multivariate survival model, each 10-unit increase in vitality score was associated with lower risk of all-cause mortality in both cohorts (Brazil HR=0.79 [95%CI 0.70 to 0.90] and United States HR=0.90 [95%CI 0.88 to 0.93], pooled HR=0.86 [95%CI 0.75 to 0.98]). Results for all models provided consistent effect estimates.
Conclusions Among patients in Brazil and the United States, lower vitality score in the initial months of PD was independently associated with all-cause mortality.
Competing Interest Statement
MG, LW, CRG, VMR, CM are students at Pontificia Universidade Catolica do Parana. CRG is a student at Johns Hopkins Bloomberg School of Public Health. VMR, CM, YJ, JWL, LAU, FWM are employees of Fresenius Medical Care. PK is an employee of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. LAU, PK, FWM have share options/ownership in Fresenius Medical Care. JWL, LAU, PK, FWM are an inventor on patent(s) in the field of dialysis. PK receives honorarium from Up-To-Date and is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research. FWM has directorships in Fresenius Medical Care Management Board, Goldfinch Bio, and Vifor Fresenius Medical Care Renal Pharma. RPF, TPM are employed by Pontificia Universidade Catolica do Parana, and are recipients of scholarships from the Brazilian Council for Research (CNPq). RPF is employed by Arbor Research Collaborative for Health, and receives research grants, consulting fees, and honoraria from AstraZeneca, Novo Nordisc, Akebia Therapeutics, and Fresenius Medical Care. JWL, PB, TPM are guest editors on the Editorial Board of Frontiers in Physiology.
Funding Statement
The study analysis in the Brazil and the United States cohorts were supported by Pontificia Universidade Catolica do Parana and Fresenius Medical Care, respectively. The Brazil cohort (BrazPD) study conduct was funded by Baxter Healthcare, Brazil.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The BRAZPD II observational cohort data were captured prospectively in a de-identified manner under a protocol approved by the Pontificia Universidade Catolica do Parana Ethics Review Board (Curitiba, Parana, Brazil; approval number 25000.187284/2004-1), and all patients provided informed consent. Data from the national network of dialysis centers in the United States was de-identified and the analysis was conducted under a protocol approved by New England Independent Review Board (Needham Heights, MA, United States; NEIRB# 17-1334030-1) with a waiver of informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used for this analysis are not publicly available. Reasonable requests to access data may be considered under executed contractual agreements between institutions.
